AstraZeneca (AZN) lines up €2.55B in new Eurobonds
Rhea-AI Filing Summary
AstraZeneca PLC (AZN) reports that its wholly owned subsidiary AstraZeneca Finance LLC has priced a €2.55 billion Eurobond offering as part of its long term funding strategy. The offering, expected to close on 1 September 2026 subject to customary conditions, comprises four tranches of fixed rate notes fully and unconditionally guaranteed by AstraZeneca PLC.
The tranches include €700 million notes with a 3.402% coupon maturing 1 March 2030, €600 million notes with a 3.652% coupon maturing 1 September 2032, €500 million notes with a 3.923% coupon maturing 1 September 2035, and €750 million notes with a 4.169% coupon maturing 1 September 2038.
AstraZeneca expects to use the net proceeds for general corporate purposes. The notes will be issued under the Company’s Euro Medium Term Note programme and admitted to listing on the UK Financial Conduct Authority’s Official List and to trading on the London Stock Exchange’s Main Market. Barclays Bank PLC, Goldman Sachs International and Morgan Stanley acted as joint book-running managers.
Positive
- None.
Negative
- None.
Filing Explained
The Notes have not been registered under the U.S. Securities Act and may not be offered or sold in the United States without registration or an applicable exemption.
Key Figures
Total Eurobond offering: €2.55 billion
2030 notes: €700 million at 3.402%
2032 notes: €600 million at 3.652%
+3 more
6 metrics
Total Eurobond offering
€2.55 billion
Aggregate principal amount of four Eurobond tranches priced on 24 August 2026
2030 notes
€700 million at 3.402%
Fixed rate notes maturing on 1 March 2030
2032 notes
€600 million at 3.652%
Fixed rate notes maturing on 1 September 2032
2035 notes
€500 million at 3.923%
Fixed rate notes maturing on 1 September 2035
2038 notes
€750 million at 4.169%
Fixed rate notes maturing on 1 September 2038
Expected closing date
1 September 2026
Anticipated closing of the Eurobond offering, subject to customary conditions
Key Terms
Eurobonds, fixed rate notes, Euro Medium Term Note (EMTN) programme, joint book-running managers, +2 more
6 terms
Eurobonds financial
"successfully priced four tranches of Eurobonds totalling €2.55 billion"
fixed rate notes financial
"€700 million of fixed rate notes with a coupon of 3.402% maturing"
Debt securities that pay a set, unchanging interest rate for a specified period and return the original loan amount at maturity. They matter to investors because they offer predictable income—like a fixed rent check from a building—but their market value can still move with overall interest rates and the issuer’s credit, affecting resale price and risk if you sell before maturity.
Euro Medium Term Note (EMTN) programme financial
"The Notes will be issued under the Euro Medium Term Note (EMTN) programme"
A euro medium term note (EMTN) programme is a legal arrangement that lets a borrower issue multiple debt notes over time under one set of paperwork, often in euros but sometimes in other currencies and with different maturities. Think of it like a single menu of IOUs an issuer can use as needed; it matters to investors because it creates a steady supply of bonds with varying terms, so buyers can pick maturity and yield that fit their risk, return and liquidity needs.
joint book-running managers financial
"Barclays Bank PLC, Goldman Sachs International and Morgan Stanley acted as joint book-running managers"
Joint book-running managers are the lead banks or financial firms responsible for organizing and overseeing the sale of a large financial offering, such as a company’s stock or bonds. They coordinate efforts to set the price, attract investors, and ensure the offering is successful. Their role is important to investors because they help ensure the offering is well-managed, properly priced, and accessible to a wide range of buyers.
Official List financial
"admitted to listing on the UK Financial Conduct Authority's Official List"
An official list is the stock exchange’s published roster of companies and securities that have met the exchange’s rules and are approved for listing and public trading. For investors it signals that a company must follow specific disclosure, reporting and governance standards, which helps with transparency, potential liquidity and legal protections — like seeing a product on a store’s certified shelf rather than an unregulated market stall.
Main Market financial
"to trading on the London Stock Exchange's Main Market"
The main market is the primary listing tier of a stock exchange where larger, established companies are traded under stricter reporting and governance rules. For investors it signals greater oversight, typically better liquidity and wider analyst coverage—think of it like buying from a flagship store rather than a small pop-up: prices are easier to trade, information tends to be more transparent, and the listing carries more credibility.
FAQ
What type and size of bond offering did AstraZeneca PLC (AZN) announce?
AstraZeneca announced a €2.55 billion Eurobond offering, priced on 24 August 2026 through its wholly owned subsidiary AstraZeneca Finance LLC, with the notes fully and unconditionally guaranteed by AstraZeneca PLC as part of its long term funding strategy.
How are the €2.55 billion AstraZeneca (AZN) bonds structured by tranche and maturity?
The offering has four tranches: €700 million at 3.402% maturing 1 March 2030, €600 million at 3.652% maturing 1 September 2032, €500 million at 3.923% maturing 1 September 2035, and €750 million at 4.169% maturing 1 September 2038.
When is AstraZeneca’s (AZN) new Eurobond offering expected to close?
The Eurobond offering totaling €2.55 billion is expected to close on 1 September 2026, subject to customary closing conditions, following pricing on 24 August 2026 by AstraZeneca Finance LLC.
What will AstraZeneca (AZN) use the €2.55 billion bond proceeds for?
AstraZeneca expects to use the net proceeds from the €2.55 billion Eurobond offering for general corporate purposes, consistent with the company’s long term funding strategy as described in the report.
Where will AstraZeneca’s (AZN) new notes be listed and traded?
The notes will be issued under the Euro Medium Term Note programme of AstraZeneca and AstraZeneca Finance LLC and admitted to listing on the UK Financial Conduct Authority's Official List and to trading on the London Stock Exchange's Main Market.
Who managed AstraZeneca’s (AZN) €2.55 billion bond transaction?
Barclays Bank PLC, Goldman Sachs International and Morgan Stanley acted as joint book-running managers for AstraZeneca Finance LLC’s €2.55 billion Eurobond offering, which is fully and unconditionally guaranteed by AstraZeneca PLC.
AI-generated analysis. How Rhea-AI works. Not financial advice.
